Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$160,000.00

Preclinical testing of a mitochondrially-targeted anticancer agent

EF 2011-12

Résumé
One of the greatest challenges in anticancer research is overcoming resistance that tumours develop to anticancer drugs. We have come up with a new drug delivery vehicle that shuttles molecules to a compartment within the cell where they are able to trigger cell death, while remaining hidden from deactivating factors. We have shown that this approach is very effective in cultured cells, and will now assess activity in a mouse model of cancer.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
240683
Name
Kelley Shana O
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Preclinical testing of a mitochondrially-targeted anticancer agent
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Anticancer Therapeutics; Drug Delivery; Mitochondrial Medicine
Abstract
One of the greatest challenges in anticancer research is overcoming resistance that tumours develop to anticancer drugs. We have come up with a new drug delivery vehicle that shuttles molecules to a compartment within the cell where they are able to trigger cell death, while remaining hidden from deactivating factors. We have shown that this approach is very effective in cultured cells, and will now assess activity in a mouse model of cancer.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kelley, Shana O
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~